How could non-vitamin k antagonist oral anticoagulants change clinical practice for stroke prevention and improve outcomes in patients with newly-diagnosed atrial fibrillation?

26 August 2018 (15:50 - 16:40)

Organised by:

Abstract

Sign in to view the resources

About the speaker

Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)

6 More presentations in this session

Presentation thumbnail

Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study

Miss B. Nguyen (Groningen, NL)

Abstract Slides

Presentation thumbnail

SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation.

Doctor R. Nishinarita (Tokyo, JP)

Abstract Slides

Presentation thumbnail

Association of left atrial size with ischemic and bleeding risk scores in patients with non-valvular atrial fibrillation

Doctor L. Enriquez Rodriguez (Soria, ES)

Abstract Slides

Presentation thumbnail

High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI

Doctor R. De Caterina (Pisa, IT)

Abstract Slides

Presentation thumbnail

Atrial fibrillation and risk of pulmonary arterial hypertension. Swedisk nationwide registry study

Assistant Professor B. Hornestam (Gothenburg, SE)

Abstract Slides

Access the full session

Session thumbnail

Atrial fibrillation - General 2

The Event

ESC Congress 2018

26 August 2018 15:50 CET

You may be interested in

Congress Session

EHRA Myths - Device-detected atrial fibrillation

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Session

Treatment strategies for atrial fibrillation in heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources